What is the share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) today?
The share price of SUNPHARMA as on 25th April 2025 is ₹1789. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?
The past returns of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share are- Past 1 week: 5.35%
- Past 1 month: -1.23%
- Past 3 months: -1.00%
- Past 6 months: -2.43%
- Past 1 year: 21.41%
- Past 3 years: 95.06%
- Past 5 years: 271.52%
What are the peers or stocks similar to Sun Pharmaceutical Industries Ltd (SUNPHARMA)?
The peers or stocks similar to Sun Pharmaceutical Industries Ltd (SUNPHARMA) include:What is the dividend yield % of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?
The current dividend yield of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is 0.75.What is the market cap of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹432816.04 Cr as of 25th April 2025.What is the 52 week high and low of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?
The 52-week high of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹1960.35 and the 52-week low is ₹1377.20.What is the PE and PB ratio of Sun Pharmaceutical Industries Ltd (SUNPHARMA) stock?
The P/E (price-to-earnings) ratio of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is 45.20. The P/B (price-to-book) ratio is 6.45.Which sector does Sun Pharmaceutical Industries Ltd (SUNPHARMA) belong to?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares?
You can directly buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sun Pharmaceutical Industries Ltd
SUNPHARMA Share Price
SUNPHARMA Share Price Chart
SUNPHARMA Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SUNPHARMA Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
37.85 | 6.45 | 0.75% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
50.69 | 6.47 | 0.52% |
SUNPHARMA Analyst Ratings & Forecast
Detailed Forecast from 34 analysts
Price Upside
Earnings Growth
Rev. Growth
SUNPHARMA Company Profile
Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.
Investor Presentation
View olderSUNPHARMA Similar Stocks (Peers)
Compare with peersSUNPHARMA Sentiment Analysis
SUNPHARMA Stock Summary · February 2025
Sun Pharma is experiencing robust growth, particularly in its specialty segment, with a notable 14% increase in its India business, driven by branded generics and new product launches. However, the company faces significant operational hurdles due to regulatory compliance issues, particularly with FDA inspections affecting several facilities, which could hinder future product introductions. While lower distribution costs and a focus on emerging markets present opportunities, pricing pressures in the generic market, especially in Japan, pose challenges. The management is strategically adjusting R&D expenditures and enhancing market readiness through an expanded field force, aiming to leverage its competitive edge in pain management and specialty products despite ongoing uncertainties in revenue recognition and market dynamics.
Key Points on Sunpharma Stock
SUNPHARMA Stock Growth Drivers
6Strong Financial Performance
In Q3 FY '25, Sun Pharma reported significant financial growth, with sales reaching INR 40,090
Market Leadership and Growth in India
Sun Pharma maintained its position as the leading company in the Indian pharmaceutical market, achieving
SUNPHARMA Stock Challenges
5Decline in U.S. Sales
In Q3 FY25, Sun Pharma's U.S. sales decreased by approximately 1% year-over-year, totaling US$ 474
Regulatory Compliance Issues
The company is currently facing compliance issues, with several facilities down with the FDA. Concerns
SUNPHARMA Forecasts
Price
Revenue
Earnings
SUNPHARMA Share Price Forecast
All values in ₹
All values in ₹
SUNPHARMA Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
SUNPHARMA Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
SUNPHARMA
Income
Balance Sheet
Cash Flow
SUNPHARMA Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 29,145.28 | 32,201.59 | 27,328.22 | 30,091.40 | 33,489.09 | 34,357.31 | 39,729.96 | 44,520.20 | 49,887.17 | 53,560.61 | ||||||||||
Raw Materials | 6,724.15 | 8,402.37 | 7,193.98 | 8,302.08 | 8,929.60 | 9,328.30 | 10,459.15 | 11,349.07 | 10,370.48 | 37,429.56 | ||||||||||
Power & Fuel Cost | 545.44 | 525.09 | 559.97 | 613.60 | 621.89 | 627.09 | 702.78 | 830.05 | 760.78 | |||||||||||
Employee Cost | 4,772.31 | 4,902.30 | 5,367.05 | 5,967.09 | 6,362.35 | 6,862.23 | 7,300.83 | 8,296.03 | 9,429.06 | |||||||||||
Selling & Administrative Expenses | 5,219.20 | 5,224.61 | 4,727.00 | 5,350.33 | 6,995.37 | 6,283.41 | 7,366.88 | 9,482.36 | 11,033.19 | |||||||||||
Operating & Other expenses | 3,752.78 | 2,434.80 | 3,983.83 | 3,739.60 | 3,214.78 | 6,235.53 | 7,147.91 | 2,452.83 | 4,410.66 | |||||||||||
EBITDA | 8,131.40 | 10,712.42 | 5,496.39 | 6,118.70 | 7,365.10 | 5,020.75 | 6,752.41 | 12,109.86 | 13,883.00 | 16,131.05 | ||||||||||
Depreciation/Amortization | 1,037.53 | 1,264.75 | 1,499.84 | 1,753.25 | 2,052.78 | 2,079.95 | 2,143.74 | 2,529.43 | 2,556.64 | 2,561.96 | ||||||||||
PBIT | 7,093.87 | 9,447.67 | 3,996.55 | 4,365.45 | 5,312.32 | 2,940.80 | 4,608.67 | 9,580.43 | 11,326.36 | 13,569.09 | ||||||||||
Interest & Other Items | 523.24 | 399.80 | 517.57 | 555.25 | 302.73 | 141.43 | 127.35 | 172.00 | 238.47 | 255.79 | ||||||||||
PBT | 6,570.63 | 9,047.87 | 3,478.98 | 3,810.20 | 5,009.59 | 2,799.37 | 4,481.32 | 9,408.43 | 11,087.89 | 13,313.30 | ||||||||||
Taxes & Other Items | 2,024.92 | 2,083.50 | 1,383.28 | 1,144.78 | 1,244.66 | -104.45 | 1,208.59 | 934.85 | 1,511.51 | 1,879.56 | ||||||||||
Net Income | 4,545.71 | 6,964.37 | 2,095.70 | 2,665.42 | 3,764.93 | 2,903.82 | 3,272.73 | 8,473.58 | 9,576.38 | 11,433.74 | ||||||||||
EPS | 20.30 | 28.98 | 8.73 | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 | 39.91 | 47.65 | ||||||||||
DPS | 1.00 | 3.50 | 2.00 | 2.75 | 4.00 | 7.50 | 10.00 | 11.50 | 13.50 | 13.50 | ||||||||||
Payout ratio | 0.05 | 0.12 | 0.23 | 0.25 | 0.25 | 0.62 | 0.73 | 0.33 | 0.34 | 0.28 |
SUNPHARMA Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
SUNPHARMA Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Sun Pharmaceutical Industries Ltd | 45.20 | 6.45 | 0.75% |
Cipla Ltd | 30.41 | 4.68 | 0.84% |
Torrent Pharmaceuticals Ltd | 67.94 | 16.41 | 0.84% |
Mankind Pharma Ltd | 56.06 | 11.20 | — |
SUNPHARMA Stock Price Comparison
Compare SUNPHARMA with any stock or ETFSUNPHARMA Shareholdings
SUNPHARMA Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
SUNPHARMA Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
SUNPHARMA Shareholding Pattern
SUNPHARMA Shareholding History
Mutual Funds Invested in SUNPHARMA
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Sun Pharmaceutical Industries Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4768% | Percentage of the fund’s portfolio invested in the stock 4.16% | Change in the portfolio weight of the stock over the last 3 months -0.75% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/102 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4138% | Percentage of the fund’s portfolio invested in the stock 2.73% | Change in the portfolio weight of the stock over the last 3 months -0.27% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/98 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3718% | Percentage of the fund’s portfolio invested in the stock 3.90% | Change in the portfolio weight of the stock over the last 3 months -0.26% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/211 (0) |
Compare 3-month MF holding change on Screener
smallcases containing SUNPHARMA stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Sun Pharmaceutical Industries Ltd
SUNPHARMA Events
SUNPHARMA Dividend Trend
SUNPHARMA has increased dividends consistently over the last 5 years
Current dividend yield is 0.75%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.55 every year
Dividends
Corp. Actions
Announcements
Legal Orders
SUNPHARMA Upcoming Dividends
No upcoming dividends are available
SUNPHARMA Past Dividends
Cash Dividend
Ex DateEx DateFeb 6, 2025
Dividend/Share
₹10.50
Ex DateEx Date
Feb 6, 2025
Cash Dividend
Ex DateEx DateJul 12, 2024
Dividend/Share
₹5.00
Ex DateEx Date
Jul 12, 2024
Cash Dividend
Ex DateEx DateFeb 9, 2024
Dividend/Share
₹8.50
Ex DateEx Date
Feb 9, 2024
Cash Dividend
Ex DateEx DateJul 28, 2023
Dividend/Share
₹4.00
Ex DateEx Date
Jul 28, 2023
Cash Dividend
Ex DateEx DateFeb 8, 2023
Dividend/Share
₹7.50
Ex DateEx Date
Feb 8, 2023
SUNPHARMA Stock News & Opinions
Sun Pharmaceutical Industries and Israel-based Moebius Medical announced today the publication of two articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI), highlighting MM-II, a novel non-opioid product for the treatment of symptomatic knee osteoarthritis. MM-II is based on a proprietary suspension of large, empty, multilamellar liposomes designed to reduce joint friction and wear, thereby alleviating pain. The two publications offer complementary insights into MM-II's clinical efficacy and mechanism of action, underscoring its potential therapeutic value. The first publication presents results from a Phase 2b randomized, double-blind, placebo-controlled trial (NCT04506463), which enrolled 397 patients across the US, Europe and Asia. Findings demonstrate that a single injection of MM-II provided clinically meaningful pain relief through 26 weeks, with a favorable safety and tolerability profile. The second publication, titled 'Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,' details MM-II's unique mechanism of action. The research shows that MM-II forms a lubricative layer over cartilage surfaces, reducing friction and slowing cartilage degeneration. The authors suggest that the results of the clinical trial may be mediated through the coating of the cartilage surfaces, though additional mechanisms may contribute to the long term pain reduction seen in Phase 2b study. 'The data from these publications show that MM-II has the potential to provide durable pain relief for patients,' said Prof. Thomas J Schnitzer, MD, PhD, a rheumatologist and professor of Medicine at Northwestern University and lead author of the clinical trial manuscript. 'With limited treatment options, lack of novel treatment approaches, and concerns around opioid use, MM-II may offer a promising alternative to hyaluronic acid and steroid treatments.' Powered by Capital Market - Live
Sun Pharmaceutical Industries announced that on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit held an oral argument on the Company's appeal of the U.S. District Court for the District of New Jersey's decision that previously granted a preliminary injunction delaying the Company's launch of LEQSELVI' (deuruxolitinib) in the United States. Shortly after the oral argument concluded, on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit ruled in favour of the Company and vacated the preliminary injunction effective immediately. While the litigation between Incyte Corporation and the Company continues, the preliminary injunction is no longer in effect. The Company is no longer under a court order that delays or restricts the Company from launching LEQSELVI'. The Company will disclose LEQSELVI' launch plans in due course of time.Powered by Capital Market - Live
The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosive esophagitis of all grades. FEXUCLUE, containing Fexuprazan, is primarily used to treat acid-related disorders, including gastroesophageal reflux disease (GERD) and erosive esophagitis. It is also being studied for the prevention of NSAID-induced peptic ulcers and gastritis. Sun Pharma has obtained the rights from Daewoong Pharmaceutical, a South Korean biopharmaceutical company, to manufacture and commercialize FEXUCLUE in India. As part of the agreement, Daewoong will receive upfront and milestone payments, as well as royalties. Kirti Ganorkar, CEO of India Business, Sun Pharma, said, 'Erosive esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE is a best-in-class treatment option with the potential to bridge this gap. At Sun Pharma, we are committed to introducing innovative medicines that enhance patients' quality of life. Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on a 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24. Shares of Sun Pharmaceuticals Industries fell 3.47% to Rs 1,650 on the BSE.Powered by Capital Market - Live
Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the brand name 'FEXUCLUE''. FEXUCLUE', a novel potassium competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades. Sun Pharma has obtained rights from Daewoong Pharmaceutical Co Ltd, Korea, a biopharmaceutical company, to manufacture and commercialise FEXUCLUE'(Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.Powered by Capital Market - Live
Sun Pharmaceutical Industries has completed 100% acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million. Powered by Capital Market - Live
Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on a 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24Powered by Capital Market - Live
Sun Pharmaceuticals Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1699.6, up 0.96% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 22466.9. The Sensex is at 74002.67, up 0.24%. Sun Pharmaceuticals Industries Ltd has dropped around 0.12% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has dropped around 1.58% in last one month and is currently quoting at 20386.85, up 1.23% on the day. The volume in the stock stood at 14.7 lakh shares today, compared to the daily average of 22.43 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 1699.9, up 0.91% on the day. Sun Pharmaceuticals Industries Ltd is up 8.17% in last one year as compared to a 1.86% gain in NIFTY and a 9.69% gain in the Nifty Pharma index.The PE of the stock is 128.24 based on TTM earnings ending December 24.Powered by Capital Market - Live
Sun Pharmaceuticals Industries Ltd is up for a third straight session today. The stock is quoting at Rs 1673.25, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.71% on the day, quoting at 22337.55. The Sensex is at 73661.95, down 0.59%. Sun Pharmaceuticals Industries Ltd has slipped around 4.19% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has slipped around 5.49% in last one month and is currently quoting at 20332.1, down 0.4% on the day. The volume in the stock stood at 11.98 lakh shares today, compared to the daily average of 22.91 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 1674.7, up 1.07% on the day. Sun Pharmaceuticals Industries Ltd is up 7.36% in last one year as compared to a 1.54% jump in NIFTY and a 8.67% jump in the Nifty Pharma index.The PE of the stock is 126.1 based on TTM earnings ending December 24.Powered by Capital Market - Live
Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. For the nine-month period ending September 2024, Checkpoint reported $0.04 million in revenue and a net loss of $27.3 million. Checkpoint has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Cutaneous Squamous Cell Carcinoma (cSCC) is the second-most common type of skin cancer in the United States, with an estimated annual incidence of approximately 1.8 million cases according to the Skin Cancer Foundation. As per the terms of the contract, Sun Pharma will acquire all outstanding shares of Checkpoint and Checkpoint stockholders will receive, for each share of common stock they hold, an upfront cash payment of $4.10, without interest, and a non-transferable contingent value right (CVR) entitling the stockholder to receive up to an additional $0.70 in cash, without interest, if cosibelimab is approved prior to certain deadlines in the European Union pursuant to the centralized approval procedure or in Germany, France, Italy, Spain or the United Kingdom, subject to the terms and conditions in the contingent value rights agreement. The upfront cash payment of $4.10 per share of common stock represents a premium of approximately 66.0% to Checkpoint's closing share price on March 7, 2025, the last trading day prior to today's announcement. In connection with the transaction, Checkpoint, Sun Pharma and Fortress Biotech, Inc., Checkpoint's controlling stockholder, have entered into a royalty agreement, under which following the closing of the transaction Fortress would be entitled to receive royalty payments based on future sales of cosibelimab during a specified term, in lieu of royalty rights that were granted to Fortress in connection with its founding of Checkpoint. The transaction is expected to be completed in the second calendar quarter of 2025. Dilip Shanghvi, chairman & managing director of Sun Pharma, said: 'Combining UNLOXCYT, an FDA approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma's global presence means patients with cSCC may soon have access to an important, new treatment option. The acquisition further bolsters our innovative portfolio in onco-derm therapy.' Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24. The scrip was down 0.06% to currently trade at Rs 1609 on the BSE. Powered by Capital Market - Live
Sun Pharmaceutical Industries and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) (Checkpoint) today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. Checkpoint has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT' (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Upon completion of the transaction, Sun Pharma will acquire all outstanding shares of Checkpoint and Checkpoint stockholders will receive, for each share of common stock they hold, an upfront cash payment of $4.10, without interest, and a non-transferable contingent value right (CVR) entitling the stockholder to receive up to an additional $0.70 in cash, without interest, if cosibelimab is approved prior to certain deadlines in the European Union pursuant to the centralized approval procedure or in Germany, France, Italy, Spain or the United Kingdom, subject to the terms and conditions in the contingent value rights agreement. The upfront cash payment of $4.10 per share of common stock represents a premium of approximately 66.0% to Checkpoint's closing share price on 07 March 2025, the last trading day prior to today's announcement. The transaction is expected to be completed in the second calendar quarter of 2025. The transaction is subject to customary closing conditions, including required regulatory approvals and approval by the holders of a majority of the voting power of outstanding shares of Checkpoint common stock, and by the holders of a majority of the shares of Checkpoint common stock that are not held by Fortress or by certain other affiliates of Checkpoint. For the nine-month period ending September 2024, Checkpoint reported $0.04 million in revenue and a net loss of $27.3 million. The R&D expense for the nine-month period was $19.3 million. As of September 30, 2024, Checkpoint had a cash balance of $4.7 million, outstanding accounts payable and accrued expenses of $15.6 million, and outstanding accounts payable and accrued expenses -related party of $2.0 million. In connection with the transaction, Fortress, which holds a majority of Checkpoint's outstanding voting power, has agreed to vote in favor of the transaction.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 10.64%, vs industry avg of 9.04%
Over the last 5 years, market share decreased from 13.7% to 13.08%
Over the last 5 years, net income has grown at a yearly rate of 29.15%, vs industry avg of 15.28%